市况评论

作者

倪国权先生 (Alex Ni)
助理经理

曾任职钢材交易员及广告公司主任,所以特别喜欢研究资源类及消费类股票。欢迎来电赐教或交流心得。
电话:
22776779

HUMAN HEALTH HOLDING LTD.(1419.HK)

2026年6月15日 星期一 观看次数36

Commentary: 

Stock: 

HUMAN HEALTH HOLDING LTD. 

 

1 Month H/L: 

0.76– 0.80

Stock Code: 

1419.HK 

 

52 week H/L: 

0.74 – 1.35

Market Cap.: 

HKD 0.296 B 

 

Listing date: 

01/04/2016

Stock Outstanding: 

379,552,233 shares 

 

Listing price: 

1.38

P/E (TTM): 

11.304x 

 

Chairman & CEO: 

Chan Kin Ping

Dividend: 

0.03 (End of Year) 

 

Major Shareholdes: 

1. Chan Kin Ping & Family – 68.29%

Dividend  

Yield(annualised):

3.846%

     
         


The Human Health Holdings Limited 2025 annual report (year ended 30 June 2025), presenting financial and operational highlights amid a challenging macroeconomic environment in Hong Kong, nevertheless, the company achieved stable growth in revenue as well as profit. 

According to the annual report of the company, there are some strategic projects and initiatives the company undertake that contribute to the company's revenue and profit growth in FY2025: 

1) Acquisition of Monarch Detanl Clinic Limited. The project was completed in February 2025; After the completion, the company's dental service revenue grew 15.9% YoY, the accelerated market penetration in the high-demand dental care segment, created cross referral opportunities with general practice and specialist services. 

2) Specialist services expansion, Polyeye brand development. The company introduced an advanced diagnostic and treatment technologies through the Polyeye brand that provide high margin services. The initiatives enhanced referral pathways between GP clinics and specialist centers within the group. The specialist service became the fastest-growing segment and recorded a reveue surged 23.8% YoY,  

The company delivered resilient 2025 results - with 9.1% revenue growth as well as 8.9% in profit growth underpinned by strategic acquisitions, specialist services expansion and operational discipline. While acknowledging the marco uncertainties and competitive pressures, the Board remains cautiously optimistic, positioning the Group to capture growth opportunites driven by againg demographics, rising health awareness and continued public-private collaboration. 

「注:本人倪国权为证监会持牌人士。截至本评论文章发表日止,本人及 / 或其有联系者并无持有全部提及之证券的所有相关财务权益。」 ; Or ” I, Ni Kwok Kuen Alex, am a licensed person under the Securities and Futures Commission. Until the date this commentary was published, neither I and/or my affiliates are the beneficiary of the securities mentioned herein or are entitled to any financial interests in relation thereto. “

 
研究报告由辉立证券集团旗下于香港证监会持牌的辉立证券(香港)有限公司及/或辉立商品有限公司(「辉立」)所发报。本文所包含的资料均为辉立从相信为准确的来源搜集。辉立对有关报告所引致之任何损失或亏损概不负责。本报告所载的资料只供参考用途,并没有法律约束力,亦不构成投资建议,邀约,购入,出售任何产品。
投资涉及风险,有可能损失投资本金。你应该咨询专业人士,就本身的投资经验,财务状况,个人目标及风险取向,以提供投资意见。各类产品的风立,请参阅本公司网页http://www.phillip.com.hk「风险披露声明」。
辉立(或其雇员)可能持有本文所述有关的投资产品。此外,辉立(或任何附属公司)随时可能替向报告内容所述及的公司提供服务,招揽或业务往来。
以上资料为辉立拥有并受版权及知识产法保护。除非事先得到辉立明确书面批准,否则不应复制,散播或发布。
返回页首
联络我们
请即联络你的客户主任或致电我们。
研究部
电话 : (852) 2277 6846
传真 : (852) 2277 6565
电邮 : businessenquiry@phillip.com.hk

查询及支援
分行资料
投诉程序
关于辉立
辉立简介
招聘人才
集团网络
辉立通讯
辉立频道
最新推廣
新聞稿
查数网
登入
研究部快讯
免费订阅
联络我们